India's Weight-Loss Generic Market: Safety and Quality Concerns Amid Patent Expiry

Indian pharmaceutical companies are preparing to manufacture generic versions of Novo Nordisk's weight-loss drugs Ozempic and Wegovy after the patent expires in March 2026. The domestically produced generics are expected to reduce prices by 50-70%. However, the rapid growth of the market also carries risks, including the question of quality and the danger of rampant counterfeiting. Indian generic manufacturers must ensure the safety of their products to maintain public trust and credibility.